Owkin and AstraZeneca developed an AI pre-screen that flags likely gBRCA mutation carriers from digitised pathology slides.
BRCA testing is inconsistently offered to eligible breast cancer patients, and the testing journey can take months. Owkin built an AI pre-screening tool that identifies patients at high risk of gBRCA mutations from digitised pathology slides in under one hour. The page says it could identify thousands more eligible patients across five European countries by 2030, and that the tool remains in development and validation.
Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Owkin on its own site — read the original case study on owkin.com ↗
Related use cases
- 01Boehringer Ingelheim used Owkin's K Pro multi-omic reports to prioritize targets and find spatially informed patient-selection biomarkers.
- 02Epkin used Owkin's K Pro to map prostaglandin biology and design the Phase 1 strategy for OKN4395.
- 03An oncology pharma used Owkin's K Pro and MOSAIC data to triage bispecific ADC candidates in silico.
- 04Owkin's K Pro Autopilot agent proposed a KRAS G12D drug combination that widened eligible patients from about 10% to 60%.
- 05Cleveland Clinic Abu Dhabi cut cohort assembly from days or weeks to seconds with Owkin's data transformation AI and K Pro.
- 06Owkin's MesoNet model predicts mesothelioma survival from pathology images and could shrink Phase 3 trial sizes.